Serum Periostin Levels in Newly Diagnosed Multiple Myeloma: Preliminary Observations and Treatment-related Changes

Serum Periostin Levels in Newly Diagnosed Multiple Myeloma: Preliminary Observations and Treatment-related ChangesAim: This study aimed to perform a descriptive evaluation of serum periostin levels in newly diagnosed, treatment-naive multiple myeloma (MM) patients and to explore short-term changes following induction therapy.Methods: Between May 2020 and May 2021, patients diagnosed with MM and healthy volunteers were recruited from the Hematology Unit of the Faculty of Medicine, Necmettin Erbakan University.Demographic characteristics, MM-related clinical findings, and treatment response data of the patients were documented.Serum periostin levels in MM patients before treatment were compared with those in healthy controls.Additionally, baseline periostin levels in the patient group were compared with post-treatment values.Results: Thirty-six MM patientswere included in our study (17 females, 47.2%; 19 males, 52.8%), with an average age of 63.11±12.13years.The control group consisted of 18 males (50%) and 18 females (50%), with a mean age of 61.94±10.53years.Serum periostin levels were significantly elevated in the MM group compared with controls healthy (25.25 ng/mL vs. 14.84 ng/mL, p